Editorials Primary hyperoxaluria
Terminal renal failure before the end of the third decade of life is the fate of most patients with primary hyperoxaluria. This rare, autosomal, recessively-inherited disorder of metabolism presents clinically with recurrent nephrolithiasis and progressive nephrocalcinosis associated with a continuous high urinary oxalate excretion and, in the later stages, systemic calcium oxalate crystal deposition (oxalosis) . There are at least two inborn errors of metabolism which result in hyperoxaluria (Williams & Smith I968a) : Type I primary hyperoxaluria is thought to be due to a deficiency of the enzyme 2-oxoglutarate glyoxylate carboligase which results in a hyperglyco1Iic aciduria in addition to the hyperoxaluria (Koch et al. 1967) . Type II primary hyperoxaluria, in which there is an increased excretion of L-glyceric acid accompanying the hyperoxaluria, is thought to be caused by a deficiency of D-glyceric acid dehydrogenase (Williams & Smith I 968b) . Type I is much the commoner and only four cases of Type II have been reported in the literature. Other distinct metabolic variants of primary hyperoxaluria are also occasionally seen (Bourke et al. 1972) .
The first case of primary hyperoxaluria was described in 1925 (Lepoutre 1925) , but it was not until the 1950s that the condition was generally recognized and many sporadic case reports appeared which enabled a more complete clinical and biochemical picture of the disease to be built up, as well as suggesting its familial character. Archer et al. (1957) suggested the term 'primary hyperoxaluria' to distinguish the metabolic abnormality from the raised urine oxalate levels found following the ingestion oflarge quantities ofoxalic acid.
Over the years progress in the understanding of disorders of oxalate metabolism has been hampered by technical difficulties in measuring the plasma and urinary oxalate concentrations. There are now several satisfactory methods of measuring the urine oxalate and the generally accepted upper limit for the twenty-four hour urinary excretion is 0.5 mmol (45 rng) (Dempsey et al. 1960 , Ribeiro & Elliot 1964 , Hodgkinson & Wilkinson 1972 , Hallson & Rose 1974 . There is as yet no general agreement about the best method of measuring the plasma oxalate, and results from various centres using different methods have shown a disparity of a hundred-fold in normal subjects (Hodgkinson 0141-0768/80/080541-04/$01.00/0 1977). A recent paper (Constable et al. 1979) described a method in which an infusion of radioisotopically-labelled oxalate, after a suitable period of equilibration, allowed an accurate assessment of renal oxala te clearance to be made; by obtaining the ratio of isotopically-labelled oxalate to chemically-measured oxalate in the urine, it was also possible to calculate the plasma concentration and the exchangeable oxalate pool. Using this method a normal range of plasma oxalate of 0.75-1.5 umol/l was obtained. Akcay & Rose (1979) have demonstrated that normal blood generates oxalate on standing and that this can be prevented by substances which inhibit the oxidation of glyoxylate. This is the probable explanation for the major discrepancies in plasma oxalate estimations and in particular explains why the derived estimation using the radioisotopic method is much lower than all the more direct measurements.
The diagnosis of primary hyperoxaluria should be suspected in young patients who form multiple radio-dense renal stones and may usually be con finned by measuring the twenty-four hour urinary oxalate excretion. In most patients with the disease this will be greater than 1 mmol (90 mg)/24 hours. The type of primary hyperoxaluri a may be distinguished by measuring the urinary glycollic acid excretion (Kasidas & Rose 1979) . Occasionally in patients with advanced renal failure it may be necessary to measure the plasma oxalate and the exchangeable oxalate pool to con finn the diagnosis. Although oxalic acid accumulates in the bodies of all chronic renal failure patients, the levels in the plasma and the exchangeable pool are set much higher in primary hyperoxaluric renal failure at any given level of creatinine clearance (Constable et al. 1979) . All siblings of patients with primary hyperoxaluria should be screened for the disease. The absence of renal calculi or nephrocalcinosis on X-ray examination does not exclude the diagnosis, therefore the best screening method is the measurement of the twenty-four hour urinary oxalate excretion.
Many drugs have been used in the attempt to reduce the endogenous formation of oxalic acid. Allopurinol, disulfiram (Gibbs & Watts 1967), calcium carbimide (Solomons et 01. 1967), succinimide (Thomas et al. 1971 , Hodgkinson et 01. 1975 , thiamine (King & Lehner 1971), tyrosine (Zinsser & Karp 1973) , isocarboxazid (Watts et al, 1979) and tryptophan (Smith & Williams 1967) have been tested but, despite initial favourable reports on some, none has been shown to cause a significant reproducible reduction in endogenous oxalate formation in primary hyperoxaluria. Only pyridoxine hydrochloride' (vitamin B6) has been shown to have this reproducible effect on a proportion of patients with primary hyperoxaluria at different centres. Twenty years ago it was first reported that pyridoxine deficiency resulted in oxalate nephrocalcinosis in experimental animals (Gershoff, Faragalla et al. 1959 ) and an apparent reduction in urinary oxalate in mentally subnormal patients given vitamin B6 supplements was also noted (Gershoff, Mayer & Kulczycki 1959) . Following these reports pyridoxine was used at different centres in varying doses for varying lengths of time in the treatment of primary hyperoxaluria, and it is now accepted that in some patients with this condition therapy with vitamin B6 in large doses results in a reduced urinary excretion of oxalic acid (Smith & Williams 1967 , Gibbs & Watts 1970 , Watts 1976 , Morgan et al. 1974 , Watts et al. 1979 , Will & Bijvoet 1979 ). In the more recent reports of successful treatment with pyridoxine, a significant improvement in renal function, occurring much more gradually than the reduction in oxalate excretion, has been reported (Harrison & Rose 1978 , Will & Bijvoet 1979 . The amount of vitamin B6 which constitutes an adequate therapeutic dose is still controversial. Smith & Williams (1967) suggested that 100-ISO mg daily was sufficient in primary hyperoxaluria but more recent publications have suggested up to 1 g/24 hours (Watts 1976) .
At the St Peter's Group of Hospitals, London, 7 of 10 primary hyperoxaluric patients treated with at least 3 rng/kg of pyridoxine hydrochloride given four times each day showed a reduction of 50% or more in their urinary oxalate excretion. From this study it was also clear that failure of compliance with the prescribed drug regime and failure to treat for sufficient time to allow depletion of the large oxalate pool might result in patients being erroneously labelled as non-responsive to pyridoxine .
The mechanism of the action of pyridoxine is not known. There is no evidence of pyridoxine deficiency in primary hyperoxaluric patients. Pyridoxine reduces the urinary excretion of glycollate in addition to oxalate and this suggests that the metabolism of glyoxylate by an alternative pathway is promoted. As it is known that pyridoxine is important as a cofactor in the transamination reaction between glyoxylate and glycine (Gerritsen et al. 1969) , this is the probable site of action.
There is now considerable evidence that the urine contains potent inhibitors of calcium oxalate crystal growth, and many authors have suggested the use in primary hyperoxaluria of agents which increase the protective inhibitory activity. Best results have been obtained with the oral administration of magnesium (Dent & Stamp 1970 , Sauberlich et al. 1964 , methylene blue (Boyce et al. 1967 , Rollins & Finlayson 1973 Stamp 1970 , Smith et al. 1973 ). Smith and his colleagues have achieved very good results using orthophosphates in combination with pyridoxine and have apparently prevented nephrocalcinosis and recurrent stone formation even in patients unresponsive to pyridoxine. However they stress that orthophosphates must be used with great care in patients with impaired renal function and that they must not be used in those whose creatinine clearance is less than 30 ml/min, All authors agree that the maintenance of a large urine volume is an essential part of therapy.
Until recently, dietary oxalate was thought to be a comparatively unimportant precursor of urinary oxalate. Reports on the seasonal variations in oxalate excretion in normal subjects and stone formers first suggested the more significant place of dietary intake (Hallson et al. 1977) . Subsequent work on normal subjects demonstrated that on adding high oxalate foods in normal dietary quantities to previously low oxalate diets, the twenty-four hour urinary oxalate excretion rose well beyond normal limits (Kasidas & Rose, unpublished observation). Studies in primary hyperoxaluric patients who responded to pyridoxine showed that a further therapeutically significant reduction in urine oxalate was made by the av?idance of such oxalate-rich foods as rhubarb, spinach, beetroot, nuts, chocolate and tea (unpublished observation).
The authors of a recent paper (Watts et al. 1979 ) wrote: 'The magnitude of the hyperoxaluria in primary hyperoxaluria far exceeds the fluctuations which are due to other causes and which predispose to or initiate stone formation. Thus, a therapeutic agent for primary hyperoxaluria should reduce the urinary oxalate excretion and not rely only on increasing the inhibition component of the saturation inhibition index'. This is an excellent guideline to the therapeutic efforts which must be made when a firm diagnosis of primary hyperoxaluria has been established.
Unfortunately in most centres the majority of patients with primary hyperoxaluria still progress to terminal renal failure. Renal substitution therapy for these patients is fraught with difficulty. Peritoneal dialysis is not efficient enough to prevent the development of ischaemic lesions secondary to infiltration of the tunica media of the arteries by oxalate crystals (Arbus & Sniderman 1974 , Klauwers et al. 1969 , Zarembski et 01. 1969 . Results achieved with haemodialysis are better, but nevertheless numerous complications arise and the average survival ofpatients with primary hyperox-aluria is significantly shorter than for the other groups of patients treated with intermittent haemodialysis (Jacobs et 01. 19750, b, Boquist et 01. 1973 , Blackburn et 01. 1975 , Toussaint et 01. 1975 . Three studies (Zarembski et 01. 1966 , Rotolo et 01. 1976 , O'Regan et 01. 1979 at different centres showed very high plasma oxalate levels in all patients on regular haemodialysis, but the levels were especially high in those with primary hyperoxaluria with the obvious dangers of arterial and cardiac crystal deposition.
A 1975 report from the American College of Surgeons/National Institute of Health Renal Transplant Registry (Wilson 1975) concluded that 'oxalosis is a form of chronic renal failure that is unsuitable for treatment by renal transplantation'. Other authors reporting their own cases and reviewing the literature have suggested that cadaveric renal transplantation should be approached with great caution and that live related transplants should be avoided because of the possible susceptibility of heterozygous kidneys with the oxalosis trait (Mahony et 01. 1972 , Saxon et 01. 1974 , Halverstadt & Wenzl 1974 , Jacobs et 01. 19750, Novick et 01. 1979 . The fact that only 3 of 17 reported renal transplants in 14 patients with welldocumented primary hyperoxaluria were still functioning more than two years postoperatively initially suggests that renal transplantation may indeed not be justified in this condition. However, a recent detailed review (O'Regan et 01. 1980) of these transplant cases revealed that in 9 transplants in 7 patients either no pyridoxine or an inadequate dose (100 mg or less per day) was given. One patient was apparently completely unresponsive to pyridoxine 250 mg daily; one patient aged four years, whose transplanted kidney was free of crystal deposition fifteen months postoperatively on pyridoxine 150 mg daily, died eight months later in renal failure and it was unclear whether the terminal oxalosis resulted from the basic disease or was a complication of the failure of a rejected kidney. In two unsuccessful transplants no details of therapy were given. Two cadaveric donor primary hyperoxaluric renal transplant recipients were well five and seven years after transplantation and a live related donor (maternal) recipient was well three years postoperatively. All three were treated with pyridoxine in large doses and the two cadaveric kidney recipients were given various substances to increase oxalate crystal solubility and to prevent the aggregation of crystals.
It was concluded (O'Regan et 01. 1980)that renal transplantation should therefore be considered in renal failure due to primary oxaluria. The transplants should be carried out only in patients who have shown a response to an adequate dose of pyridoxine given for an adequate length of time (at least two weeks). Frequent haemodialysis preop-eratively and during periods of oliguria associated with acute tubular necrosis or rejection postoperatively should reduce the eventual oxalate load on the kidney and thus avoid heavy intratubular calcium oxalate crystal deposition. Patients should be instructed to maintain a high fluid intake and to avoid oxalate-rich foods. Living related donor kidneys may be preferable for transplantation as the degree of tubular necrosis is likely to be less than in cadaveric kidneys and there is no evidence· that the heterozygous kidneys are more susceptible to oxalosis than normal.
Despite the considerable progress already made in the understanding, diagnosis and treatment of primary hyperoxaluria, much remains to be done. Why the kidneys, the cardiac muscle and the vascular intima are the major sites of oxalate crystal deposition has not been discovered, although it has been suggested that local high concentrations of ionized calcium in these areas may be important (Watts 1973) . The renal clearance of oxalate is high, usually being greater than the glomerular filtration rate, which implies that at least 180 litres of extracellular fluid are cleared of oxalate every twenty-four hours with normal renal function. Progressive renal failure may occur in primary hyperoxaluria due to vascular and renal tubular damage with consequent raised oxalate levels and increased tissue calcium oxalate crystal deposition.
The basis of effective treatment is the reduction of the urinary oxalate excretion but this can be achieved, with pyridoxine hydrochloride, only in some patients. For those patients who do not respond, therapy aimed at reducing calcium oxalate crystal formation is the only treatment available. Further therapeutic progress would seem to depend on an understanding of the metabolic difference between those primary hyperoxalurics who respond and those who do not respond to pyridoxine.
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